Moderate to Severe Chronic Obstructive Pulmonary Disease study: PF-07275315 dose vs PF-07275315-dose
Official title A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov ID: NCT07363694
What this study is testing
What is PF-07275315?
This is an investigational injectable medicine being studied as a potential treatment for moderate to severe chronic obstructive pulmonary disease (COPD).
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find out if the new medicine PF-07275315 is safe and effective for treating COPD.
- Who it's for
- The study is looking for adults aged 35 to 80 who have had moderate to severe COPD for at least a year and have had at least two bad flare-ups in the last 12 months.
- What's involved
- Participants will receive either the new medicine or a fake shot (placebo) at the clinic. They will also continue their regular COPD treatments.
- Time commitment
- The study lasts about 40 weeks for the first part or 68 weeks for the second part, requiring 11 to 18 visits to the clinic.
- Phase 3: a large, late-stage study
- Time commitment: about 68 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 35 to 80
You may be able to join if
- Diagnosis of chronic obstructive pulmonary disease (COPD) for at least 12 months (based on Global Initiative for Chronic Obstructive Lung Disease...
- Spirometry values (post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] less than [\<] 70 percent (%) and...
- Continuous treatment with standard of care triple therapy of LABA + LAMA + ICS for ≥ 6 months prior to Screening Visit 1 and at a stable dose for ≥3...
- Documented history of at least 2 moderate or severe ECOPD within the last 12 months prior to Screening. Key
You likely can't join if
- Significant pulmonary disease other than COPD.
- Requirement for continuous chronic treatment with oxygen at \>4.0 liters / minute by nasal cannula or equivalent.
- Hypoxemia with a resting SpO2 \<88% while breathing ambient air (or on the participant's usual level of oxygen supplementation).
- Clinically significant cardiovascular disease, acute and/or severe left heart failure, or heart failure partial ejection fraction, and/or cor...
The study team makes the final eligibility decision.
Where it is enrolling
- Birmingham, Alabama, United States
- Dothan, Alabama, United States
- Mobile, Alabama, United States
- Phoenix, Arizona, United States
- La Palma, California, United States
- Newport Beach, California, United States
- Northridge, California, United States
- San Diego, California, United States
- Greenacres City, Florida, United States
- Kissimmee, Florida, United States
- Loxahatchee Groves, Florida, United States
- Miami, Florida, United States
- Ocala, Florida, United States
- St. Petersburg, Florida, United States
- Tampa, Florida, United States
- Winter Park, Florida, United States
- East Point, Georgia, United States
- Rincon, Georgia, United States
- Hammond, Indiana, United States
- Merrillville, Indiana, United States
+ 118 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 68 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 35 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Birmingham, Alabama, United States; Dothan, Alabama, United States; Mobile, Alabama, United States; Phoenix, Arizona, United States; La Palma, California, United States; Newport Beach, California, United States and 132 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.